Your browser doesn't support javascript.
loading
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Knopf, Philipp; Stowbur, Dimitri; Hoffmann, Sabrina H L; Hermann, Natalie; Maurer, Andreas; Bucher, Valentina; Poxleitner, Marilena; Tako, Bredi; Sonanini, Dominik; Krishnamachary, Balaji; Sinharay, Sanhita; Fehrenbacher, Birgit; Gonzalez-Menendez, Irene; Reckmann, Felix; Bomze, David; Flatz, Lukas; Kramer, Daniela; Schaller, Martin; Forchhammer, Stephan; Bhujwalla, Zaver M; Quintanilla-Martinez, Leticia; Schulze-Osthoff, Klaus; Pagel, Mark D; Fransen, Marieke F; Röcken, Martin; Martins, André F; Pichler, Bernd J; Ghoreschi, Kamran; Kneilling, Manfred.
Affiliation
  • Knopf P; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Stowbur D; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Hoffmann SHL; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
  • Hermann N; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Maurer A; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Bucher V; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Poxleitner M; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
  • Tako B; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Sonanini D; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Krishnamachary B; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Sinharay S; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Fehrenbacher B; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
  • Gonzalez-Menendez I; Division of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Reckmann F; Department of Cancer Systems Imaging, MD Anderson Cancer Center, 1881 East Rd, Houston, TX, 77054, USA.
  • Bomze D; Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
  • Flatz L; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
  • Kramer D; Institute of Pathology and Neuropathology, Department of Pathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, Tübingen University Hospital, Tübingen, Germany.
  • Schaller M; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
  • Forchhammer S; Department of Dermatology, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Bhujwalla ZM; Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
  • Quintanilla-Martinez L; Interfaculty Institute of Biochemistry, Eberhard Karls University, Tübingen, Germany.
  • Schulze-Osthoff K; Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
  • Pagel MD; Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
  • Fransen MF; Division of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Röcken M; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
  • Martins AF; Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
  • Pichler BJ; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
  • Ghoreschi K; Institute of Pathology and Neuropathology, Department of Pathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, Tübingen University Hospital, Tübingen, Germany.
  • Kneilling M; Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Röntgenweg 13, 72076, Tübingen, Germany.
Mol Cancer ; 22(1): 207, 2023 12 15.
Article in En | MEDLINE | ID: mdl-38102680
ABSTRACT
Immune checkpoint inhibitors have revolutionized cancer therapy, yet the efficacy of these treatments is often limited by the heterogeneous and hypoxic tumor microenvironment (TME) of solid tumors. In the TME, programmed death-ligand 1 (PD-L1) expression on cancer cells is mainly regulated by Interferon-gamma (IFN-γ), which induces T cell exhaustion and enables tumor immune evasion. In this study, we demonstrate that acidosis, a common characteristic of solid tumors, significantly increases IFN-γ-induced PD-L1 expression on aggressive cancer cells, thus promoting immune escape. Using preclinical models, we found that acidosis enhances the genomic expression and phosphorylation of signal transducer and activator of transcription 1 (STAT1), and the translation of STAT1 mRNA by eukaryotic initiation factor 4F (elF4F), resulting in an increased PD-L1 expression. We observed this effect in murine and human anti-PD-L1-responsive tumor cell lines, but not in anti-PD-L1-nonresponsive tumor cell lines. In vivo studies fully validated our in vitro findings and revealed that neutralizing the acidic extracellular tumor pH by sodium bicarbonate treatment suppresses IFN-γ-induced PD-L1 expression and promotes immune cell infiltration in responsive tumors and thus reduces tumor growth. However, this effect was not observed in anti-PD-L1-nonresponsive tumors. In vivo experiments in tumor-bearing IFN-γ-/- mice validated the dependency on immune cell-derived IFN-γ for acidosis-mediated cancer cell PD-L1 induction and tumor immune escape. Thus, acidosis and IFN-γ-induced elevation of PD-L1 expression on cancer cells represent a previously unknown immune escape mechanism that may serve as a novel biomarker for anti-PD-L1/PD-1 treatment response. These findings have important implications for the development of new strategies to enhance the efficacy of immunotherapy in cancer patients.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Interferon-gamma / Neoplasms Limits: Animals / Humans Language: En Journal: Mol Cancer Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Database: MEDLINE Main subject: Interferon-gamma / Neoplasms Limits: Animals / Humans Language: En Journal: Mol Cancer Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Germany